Hui-min Z. Liu

No.100 Kexue Road
Zhengzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Pharmacological inhibition of LSD1 suppresses the CD155/TIGIT immune checkpoint axis and enhances NK cell-mediated cytotoxicity in colorectal cancer.

Pharmacological inhibition of LSD1 suppresses the CD155/TIGIT immune checkpoint axis and enhances NK cell-mediated cytotoxicity in colorectal cancer.

Journal: Bioorganic chemistry

Published: June 28, 2026

Histone Deacetylase Meets Protein Degradation: Accelerating Anticancer Drug Discovery.

Histone Deacetylase Meets Protein Degradation: Accelerating Anticancer Drug Discovery.

Journal: Medicinal research reviews

Published: December 03, 2025

Identification of Novel Phenoxazine-Derived LSD1 Inhibitors Suppressing Gastric Cancer Stemness by β-Catenin Transcriptional Regulation.

Identification of Novel Phenoxazine-Derived LSD1 Inhibitors Suppressing Gastric Cancer Stemness by β-Catenin Transcriptional Regulation.

Journal: Journal of medicinal chemistry

Published: October 29, 2025

Unveiling the power of quinazoline derivatives: a new frontier in targeted cancer therapy.

Unveiling the power of quinazoline derivatives: a new frontier in targeted cancer therapy.

Journal: Bioorganic & medicinal chemistry

Published: September 25, 2025

The Exploration of Indole-Based LSD1-Targeted Inhibitors for Enhanced Immune Response in Gastric Cancer via the PD-L1/PD-1 Axis.

The Exploration of Indole-Based LSD1-Targeted Inhibitors for Enhanced Immune Response in Gastric Cancer via the PD-L1/PD-1 Axis.

Journal: Journal of medicinal chemistry

Published: April 21, 2025

Comparative analysis for optimal LSD1 inhibitors evaluation techniques: pros and cons.

Comparative analysis for optimal LSD1 inhibitors evaluation techniques: pros and cons.

Journal: Journal of pharmaceutical analysis

Published: April 20, 2025

Discovery of 2-Aryl-4-aminoquinazolin-Based LSD1 Inhibitors to Activate Immune Response in Gastric Cancer.

Discovery of 2-Aryl-4-aminoquinazolin-Based LSD1 Inhibitors to Activate Immune Response in Gastric Cancer.

Journal: Journal of medicinal chemistry

Published: September 12, 2024

CD155 as an emerging target in tumor immunotherapy.

CD155 as an emerging target in tumor immunotherapy.

Journal: International immunopharmacology

Published: February 19, 2024

LSD1 in drug discovery: From biological function to clinical application.

LSD1 in drug discovery: From biological function to clinical application.

Journal: Medicinal research reviews

Published: July 21, 2023

Discovery of acridine-based LSD1 inhibitors as immune activators targeting LSD1 in gastric cancer.

Discovery of acridine-based LSD1 inhibitors as immune activators targeting LSD1 in gastric cancer.

Journal: European journal of medicinal chemistry

Published: January 30, 2023

Generation, secretion and degradation of cancer immunotherapy target PD-L1.

Generation, secretion and degradation of cancer immunotherapy target PD-L1.

Journal: Cellular and molecular life sciences : CMLS

Published: November 21, 2021

Prognostic value of nuclear FBI-1 in patients with rectal cancer with or without preoperative radiotherapy.

Prognostic value of nuclear FBI-1 in patients with rectal cancer with or without preoperative radiotherapy.

Journal: Oncology letters

Published: May 10, 2019

Showing 1-12 of 18

Last Updated: 09/26/2026